Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (May 2018)

Wednesday, July 25, 2018

Between January and May 2018, Russia imported 198.7 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 2% higher than that of the same period of 2017, and 42.7 bln RUB worth of in-bulk pharmaceutical drugs, which is in monetary terms 20.3% higher than that of the same period of 2017. The total dynamics are 4.8%.

In May 2018, Russia imported 42.6 bln RUB worth of ready-made drugs (free circulation prices), which is in monetary terms 6% higher than that of May 2017. Against 18% in February, the dynamics leave much to be desired. The import volume of in-bulk drugs is 6.8 bln RUB, which is 8% lower than that of May 2017.

In physical terms, Russia imported 726.4 mln units of ready-made drugs between January and May 2018, which is 8% lower than that of the same period of 2017. The import volume of in-bulk drugs amounted 1.8 bln minimum dosage units (MDU) over the period, which is 1.5% lower than that of the same period of 2017. The total import volume is 15.5 bln MDU, which is 4.6% lower than that of the same period of 2017.

Roche (Switzerland) is one of the leaders in the import of ready-made drugs. Its import has more than doubled, with anti-tumor drug Erivedge having contributed considerably to the dynamics (its import has increased by nearly 28 times). Celgene is one of the leaders in the import of in-bull drugs, with a 15.5 times increase. Revlimid, which is packaged in Kursk (Farmstandart-Leksredstva) has contributed a lot to the dynamics.

Read more about pharmaceutical drug import to Russia (April results): http://rncph.com/news/22_06_2018

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – May 2018)

Share: